IndiumV2, Main, Exploration, bibRecord, 000B94

Multimodal interventional molecular imaging of tumor margins and distant metastases by targeting αvβ3 integrin.

Identifieur interne : 000B94 ( Main/Exploration ); précédent : 000B93; suivant : 000B95

Multimodal interventional molecular imaging of tumor margins and distant metastases by targeting αvβ3 integrin.

Auteurs : RBID : pubmed:22505018

English descriptors

KwdEn :
- Animals, Female, Immunohistochemistry, Indium Radioisotopes (chemistry), Indium Radioisotopes (diagnostic use), Integrin alphaVbeta3 (metabolism), Mammary Neoplasms, Experimental (metabolism), Mammary Neoplasms, Experimental (pathology), Mammary Neoplasms, Experimental (radionuclide imaging), Mice, Mice, Inbred BALB C, Mice, Nude, Molecular Imaging (methods), Multimodal Imaging, Neoplasm Metastasis, Oligopeptides (chemistry), Organometallic Compounds (diagnostic use), Organometallic Compounds (pharmacokinetics), Positron-Emission Tomography, Tomography, Emission-Computed, Single-Photon (methods), Tomography, X-Ray Computed.
MESH :
- chemical , chemistry : Indium Radioisotopes, Oligopeptides.
- chemical , diagnostic use : Indium Radioisotopes, Organometallic Compounds.
- chemical , metabolism : Integrin alphaVbeta3.
- metabolism : Mammary Neoplasms, Experimental.
- methods : Molecular Imaging, Tomography, Emission-Computed, Single-Photon.
- pathology : Mammary Neoplasms, Experimental.
- chemical , pharmacokinetics : Organometallic Compounds.
- radionuclide imaging : Mammary Neoplasms, Experimental.
- Animals, Female, Immunohistochemistry, Mice, Mice, Inbred BALB C, Mice, Nude, Multimodal Imaging, Neoplasm Metastasis, Positron-Emission Tomography, Tomography, X-Ray Computed.

Abstract

α(v)β(3) integrin is involved in (tumor-induced) angiogenesis and is a promising candidate for the specific visualization of both primary tumors and of their distant metastases. Combination of radioactive and fluorescent imaging labels in a single multimodal, or rather hybrid, RGD-based imaging agent enables integration of pre-, intra-, and postoperative angiogenesis imaging. A hybrid imaging agent targeting the α(v)β(3) integrin--(111)In-MSAP-RGD (MSAP = multifunctional single-attachment-point reagent), which contains a targeting moiety, a pentetic acid (DTPA) chelate, and a cyanine dye--was evaluated for its potential value in combined lesion detection and interventional molecular imaging in a 4T1 mouse breast cancer model. SPECT/CT and fluorescence imaging were used to visualize the tumor in vivo. Tracer distribution was evaluated ex vivo down to the microscopic level. The properties of (111)In-MSAP-RGD were compared with those of (111)In-DTPA-RGD. Biodistribution studies revealed a prolonged retention and increased tumor accumulation of (111)In-MSAP-RGD relative to (111)In-DTPA-RGD. With (111)In-MSAP-RGD, identical features could be visualized preoperatively (SPECT/CT) and intraoperatively (fluorescence imaging). As well as the primary tumor, (111)In-MSAP-RGD also enabled detection and accurate excision of distant metastases in the head and neck region of the mice. Therefore, the hybrid RGD derivative (111)In-MSAP-RGD shows potential in preoperative planning and fluorescence-based surgical intervention.

DOI: 10.1002/cbic.201200034
PubMed: 22505018

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000D71
to stream Main, to step Curation: 000D71

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Multimodal interventional molecular imaging of tumor margins and distant metastases by targeting αvβ3 integrin.</title>
<author><name sortKey="Bunschoten, Anton" uniqKey="Bunschoten A">Anton Bunschoten</name>
<affiliation wicri:level="1"><nlm:affiliation>Interventional Molecular Imaging, Department of Radiology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Interventional Molecular Imaging, Department of Radiology, Leiden University Medical Center, 2300 RC Leiden</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Buckle, Tessa" uniqKey="Buckle T">Tessa Buckle</name>
</author>
<author><name sortKey="Visser, Nils L" uniqKey="Visser N">Nils L Visser</name>
</author>
<author><name sortKey="Kuil, Joeri" uniqKey="Kuil J">Joeri Kuil</name>
</author>
<author><name sortKey="Yuan, Hushan" uniqKey="Yuan H">Hushan Yuan</name>
</author>
<author><name sortKey="Josephson, Lee" uniqKey="Josephson L">Lee Josephson</name>
</author>
<author><name sortKey="Vahrmeijer, Alexander L" uniqKey="Vahrmeijer A">Alexander L Vahrmeijer</name>
</author>
<author><name sortKey="Van Leeuwen, Fijs W B" uniqKey="Van Leeuwen F">Fijs W B van Leeuwen</name>
</author>
</titleStmt>
<publicationStmt><date when="2012">2012</date>
<idno type="doi">10.1002/cbic.201200034</idno>
<idno type="RBID">pubmed:22505018</idno>
<idno type="pmid">22505018</idno>
<idno type="wicri:Area/Main/Corpus">000D71</idno>
<idno type="wicri:Area/Main/Curation">000D71</idno>
<idno type="wicri:Area/Main/Exploration">000B94</idno>
</publicationStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Female</term>
<term>Immunohistochemistry</term>
<term>Indium Radioisotopes (chemistry)</term>
<term>Indium Radioisotopes (diagnostic use)</term>
<term>Integrin alphaVbeta3 (metabolism)</term>
<term>Mammary Neoplasms, Experimental (metabolism)</term>
<term>Mammary Neoplasms, Experimental (pathology)</term>
<term>Mammary Neoplasms, Experimental (radionuclide imaging)</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Mice, Nude</term>
<term>Molecular Imaging (methods)</term>
<term>Multimodal Imaging</term>
<term>Neoplasm Metastasis</term>
<term>Oligopeptides (chemistry)</term>
<term>Organometallic Compounds (diagnostic use)</term>
<term>Organometallic Compounds (pharmacokinetics)</term>
<term>Positron-Emission Tomography</term>
<term>Tomography, Emission-Computed, Single-Photon (methods)</term>
<term>Tomography, X-Ray Computed</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Indium Radioisotopes</term>
<term>Oligopeptides</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Indium Radioisotopes</term>
<term>Organometallic Compounds</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Integrin alphaVbeta3</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Mammary Neoplasms, Experimental</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Molecular Imaging</term>
<term>Tomography, Emission-Computed, Single-Photon</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Mammary Neoplasms, Experimental</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Organometallic Compounds</term>
</keywords>
<keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Mammary Neoplasms, Experimental</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Female</term>
<term>Immunohistochemistry</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Mice, Nude</term>
<term>Multimodal Imaging</term>
<term>Neoplasm Metastasis</term>
<term>Positron-Emission Tomography</term>
<term>Tomography, X-Ray Computed</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">α(v)β(3) integrin is involved in (tumor-induced) angiogenesis and is a promising candidate for the specific visualization of both primary tumors and of their distant metastases. Combination of radioactive and fluorescent imaging labels in a single multimodal, or rather hybrid, RGD-based imaging agent enables integration of pre-, intra-, and postoperative angiogenesis imaging. A hybrid imaging agent targeting the α(v)β(3) integrin--(111)In-MSAP-RGD (MSAP = multifunctional single-attachment-point reagent), which contains a targeting moiety, a pentetic acid (DTPA) chelate, and a cyanine dye--was evaluated for its potential value in combined lesion detection and interventional molecular imaging in a 4T1 mouse breast cancer model. SPECT/CT and fluorescence imaging were used to visualize the tumor in vivo. Tracer distribution was evaluated ex vivo down to the microscopic level. The properties of (111)In-MSAP-RGD were compared with those of (111)In-DTPA-RGD. Biodistribution studies revealed a prolonged retention and increased tumor accumulation of (111)In-MSAP-RGD relative to (111)In-DTPA-RGD. With (111)In-MSAP-RGD, identical features could be visualized preoperatively (SPECT/CT) and intraoperatively (fluorescence imaging). As well as the primary tumor, (111)In-MSAP-RGD also enabled detection and accurate excision of distant metastases in the head and neck region of the mice. Therefore, the hybrid RGD derivative (111)In-MSAP-RGD shows potential in preoperative planning and fluorescence-based surgical intervention.</div>
</front>
</TEI>
<pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">22505018</PMID>
<DateCreated><Year>2012</Year>
<Month>04</Month>
<Day>25</Day>
</DateCreated>
<DateCompleted><Year>2012</Year>
<Month>11</Month>
<Day>01</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1439-7633</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>13</Volume>
<Issue>7</Issue>
<PubDate><Year>2012</Year>
<Month>May</Month>
<Day>7</Day>
</PubDate>
</JournalIssue>
<Title>Chembiochem : a European journal of chemical biology</Title>
<ISOAbbreviation>Chembiochem</ISOAbbreviation>
</Journal>
<ArticleTitle>Multimodal interventional molecular imaging of tumor margins and distant metastases by targeting αvβ3 integrin.</ArticleTitle>
<Pagination><MedlinePgn>1039-45</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/cbic.201200034</ELocationID>
<Abstract><AbstractText>α(v)β(3) integrin is involved in (tumor-induced) angiogenesis and is a promising candidate for the specific visualization of both primary tumors and of their distant metastases. Combination of radioactive and fluorescent imaging labels in a single multimodal, or rather hybrid, RGD-based imaging agent enables integration of pre-, intra-, and postoperative angiogenesis imaging. A hybrid imaging agent targeting the α(v)β(3) integrin--(111)In-MSAP-RGD (MSAP = multifunctional single-attachment-point reagent), which contains a targeting moiety, a pentetic acid (DTPA) chelate, and a cyanine dye--was evaluated for its potential value in combined lesion detection and interventional molecular imaging in a 4T1 mouse breast cancer model. SPECT/CT and fluorescence imaging were used to visualize the tumor in vivo. Tracer distribution was evaluated ex vivo down to the microscopic level. The properties of (111)In-MSAP-RGD were compared with those of (111)In-DTPA-RGD. Biodistribution studies revealed a prolonged retention and increased tumor accumulation of (111)In-MSAP-RGD relative to (111)In-DTPA-RGD. With (111)In-MSAP-RGD, identical features could be visualized preoperatively (SPECT/CT) and intraoperatively (fluorescence imaging). As well as the primary tumor, (111)In-MSAP-RGD also enabled detection and accurate excision of distant metastases in the head and neck region of the mice. Therefore, the hybrid RGD derivative (111)In-MSAP-RGD shows potential in preoperative planning and fluorescence-based surgical intervention.</AbstractText>
<CopyrightInformation>Copyright © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bunschoten</LastName>
<ForeName>Anton</ForeName>
<Initials>A</Initials>
<Affiliation>Interventional Molecular Imaging, Department of Radiology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands.</Affiliation>
</Author>
<Author ValidYN="Y"><LastName>Buckle</LastName>
<ForeName>Tessa</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y"><LastName>Visser</LastName>
<ForeName>Nils L</ForeName>
<Initials>NL</Initials>
</Author>
<Author ValidYN="Y"><LastName>Kuil</LastName>
<ForeName>Joeri</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y"><LastName>Yuan</LastName>
<ForeName>Hushan</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y"><LastName>Josephson</LastName>
<ForeName>Lee</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y"><LastName>Vahrmeijer</LastName>
<ForeName>Alexander L</ForeName>
<Initials>AL</Initials>
</Author>
<Author ValidYN="Y"><LastName>van Leeuwen</LastName>
<ForeName>Fijs W B</ForeName>
<Initials>FW</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>EB011996</GrantID>
<Acronym>EB</Acronym>
<Agency>NIBIB NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 EB009 691</GrantID>
<Acronym>EB</Acronym>
<Agency>NIBIB NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 EB009691</GrantID>
<Acronym>EB</Acronym>
<Agency>NIBIB NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 EB011996</GrantID>
<Acronym>EB</Acronym>
<Agency>NIBIB NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType>Journal Article</PublicationType>
<PublicationType>Research Support, N.I.H., Extramural</PublicationType>
<PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2012</Year>
<Month>04</Month>
<Day>13</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Germany</Country>
<MedlineTA>Chembiochem</MedlineTA>
<NlmUniqueID>100937360</NlmUniqueID>
<ISSNLinking>1439-4227</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Indium Radioisotopes</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Integrin alphaVbeta3</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Oligopeptides</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Organometallic Compounds</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>99896-85-2</RegistryNumber>
<NameOfSubstance>arginyl-glycyl-aspartic acid</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Int J Cancer. 2000 Aug 20;90(4):186-98</RefSource>
<PMID Version="1">10993959</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mol Pharm. 2011 Dec 5;8(6):2444-53</RefSource>
<PMID Version="1">22085282</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Anal Biochem. 2005 Mar 15;338(2):284-93</RefSource>
<PMID Version="1">15745749</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Biomed Opt. 2005 Sep-Oct;10(5):054010</RefSource>
<PMID Version="1">16292970</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nucl Med Biol. 2006 Apr;33(3):349-58</RefSource>
<PMID Version="1">16631083</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2006 May;7(5):392-401</RefSource>
<PMID Version="1">16648043</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Nucl Med. 2007 Sep;48(9):1501-10</RefSource>
<PMID Version="1">17785729</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Surg Oncol. 2012 Jun;19(6):1988-94</RefSource>
<PMID Version="1">22207047</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Chem Commun (Camb). 2008 Oct 21;(39):4792-4</RefSource>
<PMID Version="1">18830495</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Nucl Med. 2007 Nov;48(11):1862-70</RefSource>
<PMID Version="1">17942800</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Bioconjug Chem. 2008 Jan;19(1):225-34</RefSource>
<PMID Version="1">18038965</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Nucl Med. 2008 Jun;49(6):879-86</RefSource>
<PMID Version="1">18483090</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mol Pharm. 2008 Jul-Aug;5(4):527-39</RefSource>
<PMID Version="1">18537262</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Bioconjug Chem. 2008 Dec;19(12):2527-34</RefSource>
<PMID Version="1">19053310</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Med. 2009;41(4):257-64</RefSource>
<PMID Version="1">19089693</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mol Imaging. 2009 Mar-Apr;8(2):101-10</RefSource>
<PMID Version="1">19397855</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Chem Commun (Camb). 2009 Jun 28;(24):3511-24</RefSource>
<PMID Version="1">19521594</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Acc Chem Res. 2009 Jul 21;42(7):969-80</RefSource>
<PMID Version="1">19489579</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Comb Chem. 2010 Jan-Feb;12(1):57-64</RefSource>
<PMID Version="1">19928910</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Drug Discov Today. 2010 Feb;15(3-4):102-14</RefSource>
<PMID Version="1">20035896</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur J Vasc Endovasc Surg. 2010 Feb;39(2):125-33</RefSource>
<PMID Version="1">20031452</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Radiology. 2010 Mar;254(3):651-4</RefSource>
<PMID Version="1">20177082</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur J Nucl Med Mol Imaging. 2010 May;37(5):1032-8</RefSource>
<PMID Version="1">20352209</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Chem Rev. 2010 May 12;110(5):2795-838</RefSource>
<PMID Version="1">20353192</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Q J Nucl Med Mol Imaging. 2010 Jun;54(3):291-308</RefSource>
<PMID Version="1">20639815</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nanotechnology. 2010 Sep 3;21(35):355101</RefSource>
<PMID Version="1">20689167</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Nucl Cardiol. 2010 Oct;17(5):897-912</RefSource>
<PMID Version="1">20552308</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Bioconjug Chem. 2010 Oct 20;21(10):1709-19</RefSource>
<PMID Version="1">20812730</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Atherosclerosis. 2010 Nov;213(1):21-9</RefSource>
<PMID Version="1">20627248</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nanotechnology. 2010 Dec 3;21(48):482001</RefSource>
<PMID Version="1">21063057</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Biomed Opt. 2011 Jan-Feb;16(1):016004</RefSource>
<PMID Version="1">21280910</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Anticancer Agents Med Chem. 2010 Dec;10(10):753-68</RefSource>
<PMID Version="1">21269250</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Biochemistry. 2011 Apr 5;50(13):2691-700</RefSource>
<PMID Version="1">21329363</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Bioconjug Chem. 2011 May 18;22(5):859-64</RefSource>
<PMID Version="1">21480671</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Surg Oncol. 2011 Sep 1;104(3):323-32</RefSource>
<PMID Version="1">21495033</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Surg Oncol. 2011 Sep;18(9):2483-91</RefSource>
<PMID Version="1">21360250</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur Urol. 2011 Oct;60(4):826-33</RefSource>
<PMID Version="1">21458154</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nat Med. 2011 Oct;17(10):1315-9</RefSource>
<PMID Version="1">21926976</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Biomaterials. 2012 Jan;33(3):867-75</RefSource>
<PMID Version="1">22024362</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Br J Radiol. 2003;76 Spec No 1:S11-22</RefSource>
<PMID Version="1">15456710</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N">Immunohistochemistry</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N">Indium Radioisotopes</DescriptorName>
<QualifierName MajorTopicYN="N">chemistry</QualifierName>
<QualifierName MajorTopicYN="Y">diagnostic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N">Integrin alphaVbeta3</DescriptorName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N">Mammary Neoplasms, Experimental</DescriptorName>
<QualifierName MajorTopicYN="Y">metabolism</QualifierName>
<QualifierName MajorTopicYN="N">pathology</QualifierName>
<QualifierName MajorTopicYN="Y">radionuclide imaging</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N">Mice, Nude</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N">Molecular Imaging</DescriptorName>
<QualifierName MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N">Multimodal Imaging</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N">Neoplasm Metastasis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N">Oligopeptides</DescriptorName>
<QualifierName MajorTopicYN="N">chemistry</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N">Organometallic Compounds</DescriptorName>
<QualifierName MajorTopicYN="Y">diagnostic use</QualifierName>
<QualifierName MajorTopicYN="Y">pharmacokinetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N">Positron-Emission Tomography</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N">Tomography, Emission-Computed, Single-Photon</DescriptorName>
<QualifierName MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS373103</OtherID>
<OtherID Source="NLM">PMC3498954</OtherID>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year>
<Month>1</Month>
<Day>13</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="aheadofprint"><Year>2012</Year>
<Month>4</Month>
<Day>13</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2012</Year>
<Month>4</Month>
<Day>17</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2012</Year>
<Month>4</Month>
<Day>17</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2012</Year>
<Month>11</Month>
<Day>2</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="doi">10.1002/cbic.201200034</ArticleId>
<ArticleId IdType="pubmed">22505018</ArticleId>
<ArticleId IdType="pmc">PMC3498954</ArticleId>
<ArticleId IdType="mid">NIHMS373103</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=IndiumV2/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B94 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000B94 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=   *** parameter Area/wikiCode missing *** 
   |area=    IndiumV2
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:22505018
   |texte=   Multimodal interventional molecular imaging of tumor margins and distant metastases by targeting αvβ3 integrin.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:22505018" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a IndiumV2

This area was generated with Dilib version V0.5.76.
Data generation: Tue May 20 07:24:43 2014. Site generation: Thu Mar 7 11:12:53 2024

	Serveur d'exploration sur l'Indium
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur l'Indium

Multimodal interventional molecular imaging of tumor margins and distant metastases by targeting αvβ3 integrin.

Multimodal interventional molecular imaging of tumor margins and distant metastases by targeting αvβ3 integrin.

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki